You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAceprometazine
Accession NumberDB01615
TypeSmall Molecule
GroupsApproved
DescriptionAceprometazine (INN) is a prescription drug with neuroleptic and anti-histamine properties. It is not widely prescribed. It may be used in combination with meprobamate for the treatment of sleep disorders. This combination is available in France under the trade name Mepronizine. [Wikipedia]
Structure
Thumb
Synonyms
10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone
Aceprometazina
Aceprometazinum
Acepromethazine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MepronizineNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII984N9YTM4Y
CAS number13461-01-3
WeightAverage: 326.456
Monoisotopic: 326.145284026
Chemical FormulaC19H22N2OS
InChI KeyXLOQNFNTQIRSOX-UHFFFAOYSA-N
InChI
InChI=1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3
IUPAC Name
1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethan-1-one
SMILES
CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O)N(C)C
Pharmacology
IndicationAceprometazine is often used in combination with meprobamate for the treatment of sleep disorders.
Structured Indications Not Available
PharmacodynamicsAceprometazine is a drug with neuroleptic and anti-histamine properties. It is not widely prescribed.
Mechanism of actionAceprometazine, acting as an H1-receptor antagonist can induce sedation by being able to cross the blood-brain-barrier and binding to H1-receptors in the central nervous system.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineAceprometazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineAceprometazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineAceprometazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAceprometazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Aceprometazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Aceprometazine is combined with 7-Nitroindazole.Experimental
AcebutololAceprometazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Aceprometazine.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Aceprometazine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Aceprometazine.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aceprometazine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Aceprometazine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Aceprometazine.Approved, Illicit, Investigational
AlprenololAceprometazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Aceprometazine.Approved, Illicit
AmodiaquineThe serum concentration of Aceprometazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amperozide.Experimental
AmphetamineAceprometazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Aop200704Aceprometazine may increase the hypotensive activities of Aop200704.Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Aceprometazine.Approved, Investigational
ArotinololAceprometazine may increase the hypotensive activities of Arotinolol.Approved
ArtemetherThe serum concentration of Aceprometazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Aceprometazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Aceprometazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Asenapine.Approved
AtenololAceprometazine may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of Aceprometazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Azaperone.Vet Approved
AzelastineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Aceprometazine.Illicit
BefunololAceprometazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Aceprometazine.Approved
BenzphetamineAceprometazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Benzyl alcohol.Approved
BetaxololAceprometazine may increase the hypotensive activities of Betaxolol.Approved
Betulinic AcidThe serum concentration of Aceprometazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololAceprometazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideAceprometazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololAceprometazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololAceprometazine may increase the hypotensive activities of Bopindolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Aceprometazine.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aceprometazine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brotizolam.Approved, Withdrawn
BucindololAceprometazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolAceprometazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Aceprometazine.Approved, Investigational
BupranololAceprometazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Aceprometazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aceprometazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Aceprometazine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aceprometazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aceprometazine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Aceprometazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Aceprometazine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Carisoprodol.Approved
CarteololAceprometazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolAceprometazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololAceprometazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Aceprometazine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aceprometazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Aceprometazine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Aceprometazine.Approved
ChloroquineThe serum concentration of Aceprometazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Chlorphenamine.Approved
ChlorphentermineAceprometazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aceprometazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Aceprometazine.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Aceprometazine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Aceprometazine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Aceprometazine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aceprometazine.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Aceprometazine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Aceprometazine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Aceprometazine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aceprometazine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aceprometazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Aceprometazine can be increased when it is combined with Dapsone.Approved, Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Aceprometazine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aceprometazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aceprometazine.Approved, Vet Approved
DextroamphetamineAceprometazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Aceprometazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Aceprometazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Aceprometazine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Aceprometazine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Aceprometazine.Approved, Illicit, Vet Approved
DiethylpropionAceprometazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Difenoxin.Approved, Illicit
DihydroartemisininThe serum concentration of Aceprometazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Aceprometazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Aceprometazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Aceprometazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Aceprometazine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Aceprometazine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aceprometazine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Doxepin.Approved
DoxycyclineThe serum concentration of Aceprometazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Aceprometazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Aceprometazine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Aceprometazine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Aceprometazine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Aceprometazine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Aceprometazine.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Aceprometazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aceprometazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aceprometazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aceprometazine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Aceprometazine.Approved, Investigational
EsmololAceprometazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Aceprometazine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aceprometazine.Approved
EthanolAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aceprometazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Aceprometazine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Aceprometazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Aceprometazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Aceprometazine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Aceprometazine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aceprometazine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Aceprometazine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Aceprometazine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aceprometazine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Aceprometazine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Aceprometazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aceprometazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Aceprometazine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Aceprometazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aceprometazine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Aceprometazine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Aceprometazine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Aceprometazine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Aceprometazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Aceprometazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Aceprometazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Aceprometazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Aceprometazine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Aceprometazine.Approved
HydrocodoneAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aceprometazine.Approved, Illicit
Hydroxyamphetamine hydrobromideAceprometazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Aceprometazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Indalpine.Investigational, Withdrawn
IndenololAceprometazine may increase the hypotensive activities of Indenolol.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aceprometazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Aceprometazine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aceprometazine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Aceprometazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ketobemidone.Approved
LabetalolAceprometazine may increase the hypotensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levetiracetam.Approved, Investigational
LevobunololAceprometazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Aceprometazine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Aceprometazine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Aceprometazine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aceprometazine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Aceprometazine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Aceprometazine.Approved, Investigational
LisdexamfetamineAceprometazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Aceprometazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aceprometazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Aceprometazine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Aceprometazine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Aceprometazine is combined with Lu AA21004.Investigational
LumefantrineThe serum concentration of Aceprometazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Aceprometazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Aceprometazine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Melperone.Approved
MephedroneAceprometazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAceprometazine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aceprometazine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aceprometazine.Approved, Illicit
MequitazineAceprometazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aceprometazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Aceprometazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Aceprometazine.Approved, Illicit
MethamphetamineAceprometazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Aceprometazine.Approved
MethotrimeprazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aceprometazine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Aceprometazine.Approved
MetipranololAceprometazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aceprometazine.Approved, Investigational
MetoprololAceprometazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineAceprometazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Aceprometazine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Aceprometazine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Investigational
MirtazapineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Aceprometazine can be increased when it is combined with Mizoribine.Investigational
MMDAAceprometazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Aceprometazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Aceprometazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Investigational
NadololAceprometazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aceprometazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Aceprometazine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Aceprometazine.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Aceprometazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Aceprometazine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Aceprometazine.Approved
OpiumThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Opium.Approved, Illicit
OrphenadrineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aceprometazine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Aceprometazine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Aceprometazine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aceprometazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Aceprometazine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Aceprometazine.Approved
ParaldehydeAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aceprometazine.Approved, Investigational
PenbutololAceprometazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aceprometazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Aceprometazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Aceprometazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aceprometazine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aceprometazine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Aceprometazine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Phenoxyethanol.Approved
PhentermineAceprometazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Aceprometazine.Approved
PindololAceprometazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pomalidomide.Approved
PractololAceprometazine may increase the hypotensive activities of Practolol.Approved
PramipexoleAceprometazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Aceprometazine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Aceprometazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Aceprometazine.Approved
PrimaquineThe serum concentration of Aceprometazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Aceprometazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aceprometazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aceprometazine.Approved, Vet Approved
ProguanilThe serum concentration of Aceprometazine can be increased when it is combined with Proguanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Aceprometazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Aceprometazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Aceprometazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Propoxycaine.Approved
PropranololAceprometazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Aceprometazine is combined with PSD502.Investigational
PseudoephedrineAceprometazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Aceprometazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Aceprometazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Aceprometazine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aceprometazine.Approved
QuinacrineThe serum concentration of Aceprometazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Aceprometazine.Approved
QuinidineThe serum concentration of Aceprometazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Aceprometazine can be increased when it is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Aceprometazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aceprometazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aceprometazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aceprometazine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Aceprometazine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Aceprometazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ritanserin.Investigational
RitobegronAceprometazine may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Aceprometazine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Romifidine.Vet Approved
RopiniroleAceprometazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Aceprometazine.Approved
RotigotineAceprometazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Aceprometazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Aceprometazine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Aceprometazine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aceprometazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Aceprometazine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Aceprometazine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aceprometazine.Approved, Vet Approved
SinefunginThe serum concentration of Aceprometazine can be increased when it is combined with Sinefungin.Experimental
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
SotalolAceprometazine may increase the hypotensive activities of Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aceprometazine.Approved, Investigational
SulfadoxineThe serum concentration of Aceprometazine can be increased when it is combined with Sulfadoxine.Approved
SulfametopyrazineThe serum concentration of Aceprometazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Aceprometazine.Approved, Investigational
SuvorexantAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Aceprometazine can be increased when it is combined with tafenoquine.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aceprometazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Aceprometazine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aceprometazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetrodotoxin.Investigational
ThalidomideAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aceprometazine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Aceprometazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiletamine.Vet Approved
TimololAceprometazine may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Aceprometazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aceprometazine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Aceprometazine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Aceprometazine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aceprometazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aceprometazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Aceprometazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Aceprometazine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Aceprometazine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Aceprometazine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Aceprometazine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aceprometazine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Aceprometazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aceprometazine.Approved, Investigational
ZolpidemAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Aceprometazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9852
Caco-2 permeable+0.8427
P-glycoprotein substrateSubstrate0.8358
P-glycoprotein inhibitor IInhibitor0.9139
P-glycoprotein inhibitor IIInhibitor0.5926
Renal organic cation transporterInhibitor0.5135
CYP450 2C9 substrateNon-substrate0.7768
CYP450 2D6 substrateSubstrate0.8188
CYP450 3A4 substrateSubstrate0.5876
CYP450 1A2 substrateInhibitor0.8793
CYP450 2C9 inhibitorNon-inhibitor0.9009
CYP450 2D6 inhibitorInhibitor0.7954
CYP450 2C19 inhibitorNon-inhibitor0.8674
CYP450 3A4 inhibitorNon-inhibitor0.7954
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5333
Ames testNon AMES toxic0.8613
CarcinogenicityNon-carcinogens0.8886
BiodegradationNot ready biodegradable0.9941
Rat acute toxicity2.6833 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9729
hERG inhibition (predictor II)Inhibitor0.7319
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP4.35ALOGPS
logP3.85ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)16.06ChemAxon
pKa (Strongest Basic)8.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity98.91 m3·mol-1ChemAxon
Polarizability36.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Benzenoid
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Mercier J, Dessaigne S, Menguy A, Manez J: Electro-encephalographic study on the action of the combination meprobamate-aceprometazine on various cerebral systems. Arzneimittelforschung. 1974 Feb;24(2):163-6. [PubMed:4406367 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 14:13 / Updated on August 17, 2016 12:23